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Abstract 
 
The development of clinical guidelines is now a more uniform process, with formalised 
methods to ensure that recommendations are based on current best available evidence from 
randomised controlled trials and systematic reviews.  Over the past 20 years we have seen a 
growth in guidelines including those relating to osteoporosis, with recommendations varying 
between and within countries. Some guidelines are concerned with case finding and primary 
or secondary prevention, such as those produced by the National Institute for Health and Care 
Excellence (NICE CG146, TA160, 161, 464), while others focus on specific conditions or risk 
factors associated with osteoporosis, such as the menopause, coeliac disease and eating 
disorder. Clinicians can be confused as to which to follow in any particular clinical scenario. 
International guidelines, such as those from North America (NOF, CAROC, AACE) and Scotland 
(SIGN 142), differ from those of England, Wales and Northern Ireland, with recent 
recommendations from NICE (TA464) shifting the focus of treatment from those at greatest 
fracture risk to an apparent blanket approach, based on cost-effectiveness, rather than 
clinical effectiveness. 
 
Osteoporosis treatment should be targeted at those who can benefit most, outweighing the 
potential for harm. If the low health economic threshold of NICE TA464 were adopted as a 
clinical threshold, the most important group – older people at greatest risk of fracture, would 
not be prioritised. We risk overwhelming clinical services, while causing harm to some at low 
fracture risk from adverse effects of treatment, yet failing to treat the older population at 
highest fracture risk. 
 
.  
  
Clinical Guideline Development 
National and international agencies such as the National Institute for Health and Care 
Excellence (NICE), the Scottish Intercollegiate Guideline Network (SIGN) and WHO [1] 
continue to refine and develop clinical guidelines, which are important tools to aid clinical 
practice. In the past, consensus “guidelines”, have sometimes been of dubious provenance 
and occasionally influenced by external parties including the pharmaceutical industry [2]. 
Almost 20 years ago it was recommended that formalised methods for clinical guideline 
development should result in a five stage process [3]: 
 
1. Identify and refine the subject area (the question) 
2. Convene a guideline development group 
3. Assess the evidence, based on systematic reviews 
4. Translate evidence into a recommendation within a clinical practice guideline 
5. Perform external review of the guideline 
 
This was a major breakthrough at the time, focusing on the definition of clinical questions and 
the synthesis of best available evidence from randomised trials.  In practice, rather than over-
interpreting individual clinical study results suggesting drug efficacy, this promoted the use 
of clinical evidence. However, many important operational considerations for the 
development of clinical guidelines remain: the refinement of the clinical question; defining 
appropriate competencies of the guideline development group members and, more recently, 
the role of patient and public involvement have become critical to guideline development [4]. 
Whatever the clinical questions identified, there will be cases where the quality of the 
evidence is poor or completely absent, and this must be taken into account in the weighting 
of recommendations. For example, should the advice be a “must do” or “consider doing”? 
Moreover, the final review tends to be technical, rather than clinical, and it is not surprising 
that there are guidelines on the development of guidelines, including those produced by 
academic and government bodies [3, 5, 6].  Health economics have become key to guideline 
development, with NICE addressing a number of questions relating to access to expensive 
interventions and, together with the Scottish Health Consortium, a “threshold” for 
treatments to be recommended for use in the NHS is typically between £20,000 and £30,000 
per Quality Adjusted Life Year (QALY) gained.  
 
Osteoporosis Guidelines 
The use of health economic thresholds incorporating QALYs led to some difficulties with 
previous NICE technology appraisals for osteoporosis [7], as the costs of treatments meant 
that patients with osteoporosis confirmed by dual energy X-ray absorptiometry (DXA) would 
not have access to drugs, since estimated health costs exceeded £20,000/QALY [6]. In 
response, the National Osteoporosis Guideline Group (NOGG) developed evidence based 
guidelines with alternative treatment thresholds, which were not set using health economic 
considerations but the clinical fracture risk after a first low trauma fracture [8]. Whereas, SIGN 
guidelines took an alternative approach, interpreting clinical trial-based evidence to support 
drug treatment for those who have had a vertebral fracture, hip fracture or with a bone 
mineral density (BMD) T-score less than -2.5 [9]. There are now a number of guidelines on 
osteoporosis across Europe and North America, with country- and comorbidity-specific 
recommendations, including those produced in the United Kingdom. Each takes a slightly 
different approach, resulting in inconsistent recommendations (see Table 1).     
 Table 1 comparison of osteoporosis guidelines  
 
Guideline title 
(year) Country 
Patient group 
or population 
Drugs 
included 
Treatment thresholds  
(clinical or densitometric) 
Comments 
 
 
United Kingdom 
NICE TA160 
(2008)*  
England and 
Wales 
Postmenopausal 
women. Primary 
prevention 
alendronate, 
risedronate, 
etidronate, 
raloxifene, 
strontium 
ranelate 
 T-score < -2.5 by DXA  Teriparatide not cost effective  
 Zoledronate not considered.  
 Oral bisphosphonates (BP) first line & other agents only allowed at much  
higher fracture risk. 
NICE TA161 
(2008)*  
England and 
Wales 
Postmenopausal 
women. 
Secondary 
prevention after 
fragility fracture 
alendronate, 
risedronate, 
etidronate, 
raloxifene, 
strontium 
ranelate, 
teriparatide 
 T-score < -2.5 
 For age ≥75 years: could 
treat without BMD by DXA 
 Zoledronate not considered 
 Oral BF first line 
 Other agents only allowed at much lower T-scores and additional risk 
factors. 
NICE TA 204 
(2014)  
England and 
Wales 
Postmenopausal 
women.  
Primary and 
secondary 
prevention 
denosumab  Oral bisphosphonate 
intolerant, contraindicated 
or failed.  
 Primary prevention  
T-score ≤ -4.0 and/or risk 
factors 
 Secondary prevention 
satisfies criteria for TA161  
 Only applies to denosumab. Very difficult thresholds to meet for primary 
prevention. 
 Difficult now (2017) as NICE TA 464 for BF is available and denosumab 
update awaited 
*NICE TA 464 
(2017) 
England and 
Wales 
Men & women alendronate, 
ibandronate, 
risedronate, 
zoledronate 
 Oral BP 
 IV BP if 10-year fracture 
risk is ≥10% or  
 ≥1% and oral 
bisphosphonates 
 Replaces TA160 and 161 recommendations on bisphosphonates 
 Denosumab guidance awaited. 
 Uses FRAX or QFracture to estimate fracture risk.  
 Analysis shows that medications are cost effective down to low levels of 
risk because of their low cost. However, these are not treatment 
intolerant, contraindicated 
or failed 
thresholds and NOGG guidance highlighted as a possible clinical guideline 
to treatment.  
NICE CG146 
(2012)  
England and 
Wales 
Men & women No specific 
treatments 
considered 
 None treatment 
thresholds 
 Use FRAX or QFracture to 
determine fracture risk: 
o Women/men 
65+/75+ years.  
o At younger age 
use other risk 
factors 
 Case finding 
 No treatment thresholds.  
 BMD measured after performing fracture risk assessment. 
 Comes after NICE TA 160, 161 and 204, but a recognition that fracture 
risk should influence decisions about fracture prevention.  
NOGG (2009 and 
updated 2017) 
United Kingdom 
[8] 
Men and women 
over 40 years 
alendronate, 
risedronate, 
zoledronate, 
HRT, 
raloxifene, 
strontium, 
denosumab 
and 
teriparatide 
 10-year fracture risk used 
 Men and women aged 70+ 
years 
o with a fracture or  
o on long term 
prednisolone 
over 7.5 mg daily 
should be considered for 
bone protection 
 FRAX used without BMD to determine fracture risk (high, low or 
medium), then refine into high or low risk.  
 Calculate risk to age 70+ years, thereafter fixed risk of 20% for major and 
5% for hip fracture used. 
 Oral BP first line. 
 No alteration to threshold for use of alternative agents 
 High cost of teriparatide restricts use for those at very high risk of 
vertebral fractures.  
 Incorporates guidance on investigation and management of osteoporosis 
including vitamin D and falls 
SIGN 142 
(2015)  
Scotland [9] 
Men and women 
Over 50 years 
alendronate, 
risedronate, 
ibandronate, 
etidronate, 
zoledronate, 
denosumab, 
HRT,  
tibolone, 
raloxifene, 
strontium 
ranelate,  
teriparatide 
 Primary prevention FRAX 
risk ≥ 10% for major 
fracture and T-score ≤ -2.5 
 Secondary prevention at 
least one fragility fracture 
and a T-score ≤ -2.5 
 Hip fracture 
 Vertebral fracture 
Once over threshold any treatment may be used, but: 
 1st line alendronate and risedronate.  
 Teriparatide if severe spinal osteoporosis 
 2nd line zoledronate or denosumab 
 3rd line ibandronate, etidronate, HRT, tibolone, raloxifene and strontium 
 Treatment can be initiated without BMD measurements in 
o Vertebral fracture patients  
o Hip fracture patients, where zoledronate should be offered 
 Europe 
ESCEO and IOF 
(2008 updated 
2013)  
Europe [10] 
Postmenopausal 
women 
alendronate, 
ibandronate, 
risedronate, 
zoledronate,  
HRT,  
PTH 
therapies, 
raloxifene, 
calcitonin, 
denosumab, 
strontium 
ranelate 
 10-year fracture risk using 
FRAX 
 Country specific 
thresholds for treatment.  
 If prior fracture, consider 
treatment without further 
risk assessment. 
 Does not specify order of use of medications 
 Note that cost alone would suggest alendronate as first line. 
 DXA depends on country e.g. very good access in Belgium, but very 
difficult in Bulgaria.  
 Offers advice on investigation, vitamin D, management and falls 
prevention 
 
North America 
Scientific 
Advisory council 
of osteoporosis 
Canada (2010) 
Canada [11] 
Men and women 
over 50 
Alendronate, 
etidronate, 
risedronate, 
zoledronate, 
raloxifene, 
PTH 
therapies and 
denosumab 
 Based on FRAX or CAROC 
fracture risk calculation 
 10-year major 
osteoporotic fracture risk 
≥ 20%.  
 Aged over 50 years with a 
hip, vertebral or multiple 
fractures are high risk. 
 T score ≤ -2.5 moderate 
risk and moderate risk 
needs combining with 
additional risk factors and 
patient preference 
 Includes information on investigation and management as well as falls 
risk.   
 Vitamin D checked and targeted ≥ 75nmol/L in those requiring treatment 
 First line treatment 
o Women: alendronate, risedronate, zoledronate and denosumab 
o Men: alendronate, risedronate, zoledronate and testosterone. 
NOF (2014)  
USA [12] 
Men and women 
over 50 years 
FDA 
approved 
medications: 
alendronate, 
ibandronate, 
 Treatment should be 
considered for: 
o hip or vertebral 
fracture 
 Does not give an order for 1st line or 2nd line agents. 
 Just recommends the use of an FDA approved medication.  
risedronate, 
zoledronate, 
calcitonin,  
raloxifene, 
bazedoxifene
, teriparatide, 
denosumab 
o T-score ≤ -2.5 at 
hip or spine on 
DXA. 
o T-score between  
-1.0 & -2.5  with a 
10-year risk ≥ 
20% for major 
fracture or ≥ 3% 
for hip fracture.  
AACE/ACE (2016)  
USA [13] 
Postmenopausal 
women. 
alendronate, 
ibandronate, 
risedronate, 
zoledronate, 
raloxifene, 
teriparatide, 
denosumab 
T-score ≤ -2.5 at femoral neck, 
total hip or lumbar spine  
or 
A history of fragility fracture or  
FRAX probability of ≥ 20% for a 
major fracture or hip fracture ≥ 
3% 
FDA approved medications considered 
Different choices of first or second line depending on situation. 
No previous fracture then 1st line would be alendronate, risedronate, 
zoledronate or denosumab. 
2nd line ibandronate or raloxifene. Switch to injectables if problems with oral 
BP or to teriparatide. 
Prior fractures 1st line denosumab, zoledronate or teriparatide. Alternatives 
alendronate/risedronate or switch to teriparatide. 
 
Abbreviations: NICE, national institute for health and care excellence; NOGG, national osteoporosis guidance group; SIGN, Scottish intercollegiate 
guidelines network; ESCEO, European society for clinical and economic aspects of osteoporosis; IOF = International osteoporosis foundation; 
CAROC, Canadian Association of Radiologists and Osteoporosis Canada; NOF, National Osteoporosis Foundation; AACE, American association of 
Clinical Endocrinologists;  ACE, American College of Endocrinology.  
NICE guidelines can be found at https://www.nice.org.uk/guidance [14] 
 
 
 
 
NICE guidance  
The history of osteoporosis guidelines is complex in the United Kingdom: For England, Wales 
and Northern Ireland, NICE took six years to complete health technology appraisals (TAs) to 
provide recommendations for the primary (TA160) and secondary (TA 161) prevention of 
osteoporotic fragility fractures in postmenopausal women using alendronate, etidronate, 
risedronate, raloxifene, teriparatide and strontium ranelate in 2008, followed by denosumab 
(TA204) in 2010. However, these guidelines were out of date by the time they were published, 
as the health economic analysis had been performed on oral bisphosphonates priced at the 
cost of branded rather than generic products. This resulted in high thresholds of fracture risk 
(summarised by clinical risk factors and BMD measurements) required for the use of 
alendronate and even higher risks (and lower BMDs) required for the prescription of 
alternative drugs. Clinicians found that, in patients intolerant of alendronate but at high risks 
for osteoporotic fracture, NICE criteria and treatment thresholds did not permit alternative 
clinically effective medications. 
 
The development of osteoporosis guidelines remains work in progress for NICE, which has 
more recently started to update guidance and expand its remit to the treatment of 
osteoporosis in women and men. Guidance on oral and intravenous bisphosphonates 
(TA464), published this year, is radically different from previous technology appraisals (TA160 
and TA161), while guidance on abaloparatide, raloxifene, teriparatide and denosumab are in 
development (ID901). Although strontium ranelate is supposed to be under consideration, it 
is no longer available in the UK and therefore not to be considered any further here. The 
clinical guideline on fracture risk assessment (CG146) was a useful development by NICE, as 
it offers the currency of 10-year fracture risk to guide treatment decisions, although not 
providing treatment thresholds, suggesting that these could subsequently be developed, 
based on fracture risk. However, there remains the problem of translating clinical trial 
evidence, almost universally from studies using BMD criteria, to treatment according to 
fracture risk per se. By comparison, the SIGN guideline (SIGN 142) is a comprehensive review 
of case finding, including a range of specific risk factors, treatment thresholds and guidance 
on duration of therapy. It is less enthusiastic about the use of clinical risk factors to decide on 
treatment, but prefers QFracture over FRAX, arguing that the former has a more transparent 
methodology, UK validation, value over a wider age range, in different ethnic groups, and 
over varying timeframes. However, NICE CG146 failed to find any calibration data to suggest 
superiority of either method over the other in predicting fractures. 
  
The key osteoporosis guidelines from NICE are on the estimation of fracture risk (CG 146) and 
guidance on primary (TA160) and secondary prevention (TA161), with the recent update on 
bisphosphonate treatment (TA464), which will be complemented by further technology 
appraisals on other agents (ID901).  However, NICE guidelines for a range of conditions and 
specific guidance with reference to a number of therapies vary in their consideration of 
osteoporosis [14], and recommendations on the management of osteoporosis and fracture 
risk overlap across a range of conditions.  Guidelines on hip fracture (CG124), coeliac disease 
(NG20), and falls (CG161) all cross references to CG146, but guidelines on vertebroplasty 
(IPG12), kyphoplasty (IPG166), cystic fibrosis (NG78) and complex fractures (NG37) make no 
references to treatment of osteoporosis or fracture prevention. The prostate cancer guideline 
(CG175) refers to CG146 and also offers specific advice on the use of bisphosphonates and 
denosumab. However, the eating disorder guidelines (NG69) recommend bisphosphonate 
therapy as well as the avoidance of high-impact exercise, but the menopause guidelines 
(NG23) reference the skeletal benefits of hormone replacement therapy in affected women 
without directly advocated treatment to protect the skeleton. There are also specific 
recommendations on treatment of risk for familial breast cancer (CG164) with raloxifene for 
women who have severe osteoporosis or do not wish to take anastrozole. Guidance on the 
management of therapy-induced bone loss in non-metastatic breast cancer (ID83) is also in 
development. Perhaps the most contentious NICE recommendation on osteoporosis, and 
extremely relevant for older patients, is the guideline on multimorbidity (NG56), which 
suggests that there is no evidence of benefit from continuing bisphosphonate therapy beyond 
3 years. 
 
Where are we now? 
In late 2017, clinicians are faced with an overwhelming amount of guidance on the 
management of osteoporosis and bone health from international [1, 10, 12, 13], national [8, 
9, 14] and local [15] sources.  Internationally, there are considerable variations in practice as 
shown in table 1. In England, Wales and Northern Ireland, the range of NICE guidelines and, 
in particular, health technology appraisal guidance are clear reference points. In Scotland, 
SIGN 142 is likely to be most influential, although many clinicians south of the border adopt 
clinical strategies based on SIGN, which are attractive in their comprehensive coverage of 
case finding, treatment choice and duration, with a focus on evidence of clinical efficacy, 
rather than health economic evaluation.  The most recent recommendations from NICE are a 
radical change, with no health economic argument against oral or parenteral therapy down 
to a 10-year fracture risk of 1%. However, it recently has been suggested that “Unthinking 
assimilation of the NICE multiple technology appraisal risks a generation of older individuals 
taking a bisphosphonate regardless of the individual benefit-to-risk ratio”[16].   
 
Reviewing the health economic analysis supporting the NICE guidance, it appears that 
gastrointestinal adverse effects but not atypical femur fracture (estimated at 0.13% per 
annum [17]) or osteonecrosis of the jaw (estimated 1/10,000 and 1/100,000 person-years 
[18]) or external auditory meatus (reported but incidence unknown) were included in the 
estimation of DALYs lost. Giving bisphosphonates to patients with a 10-year risk of fracture of 
1%, health costs of rarer but serious adverse outcomes become a real concern. Using a 
conservative estimate for 10-year risk of atypical femur fracture on bisphosphonate therapy 
of around 1%, treating 1,000 patients for 10 years, at this level of risk, we can anticipate 
preventing 5 fractures (including 3 hip fractures) but seeing 10 atypical (subtrochanteric) 
fractures and 1 case of osteonecrosis of the jaw. Moreover, the NICE health economics 
models were based on 6 months’ treatment effect and so does not consider poor adherence 
to oral treatment. For intravenous treatment, a generic drug cost was used and the real world 
costs may differ, depending on whether they include day case charges and blood testing. The 
inconsistency of recommendations from NICE with regard to duration of treatment also needs 
clarification, as NG56 multimorbidity guidance recommends treatment for only 3 years, 
whereas NOGG and (for Scotland) SIGN suggest 5 or 10 years.  Finally, we are left with out-
of-date guidance on denosumab and teriparatide, referring still to technology appraisals 204 
and 161.   
 
 Treating older patients at risk of osteoporotic fracture 
What should we do to prevent osteoporotic fracture, particularly for older patients? 
Historically, we may have focused on the prescription of calcium and vitamin D 
supplementation in older patients. However, it seems logical to target bisphosphonates at 
older people who are at greatest fracture risk, although inexpensive therapy is not being 
offered to many [19]. So, we should target those at greatest risk of hip fracture, perhaps using 
NICE CG146. Complementing this, secondary prevention through fracture liaison services and 
case identification of prevalent vertebral fractures would help identify those at risk of future 
fracture. With finite health resource and practitioner time, a misinterpretation of the latest 
NICE guidance (TA 464) as a licence to treat all patients at a 10-year fracture risk greater than 
1% would be a disaster. We risk overwhelming clinical services with treatment and causing 
harm to some of those at low fracture risk with adverse effects of treatment, while possibly 
failing to treat the older population at highest fracture risk.  
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